

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.e-jmii.com

ORIGINAL ARTICLE

Virulence factors, antibiotic resistance phenotypes and O-serogroups of *Escherichia coli* strains isolated from community-acquired urinary tract infection patients in Mexico

Gloria Luz Paniagua-Contreras^a, Eric Monroy-Pérez^a,
José Raymundo Rodríguez-Moctezuma^b,
Pablo Domínguez-Trejo^b, Felipe Vaca-Paniagua^a,
Sergio Vaca^{a,*}

^a FES Iztacala, Universidad Nacional Autónoma de México, Estado de Mexico, Mexico

^b Unidad Médica Familiar Number 64, Instituto Mexicano del Seguro Social, Juárez, Mexico

Received 15 April 2015; received in revised form 24 June 2015; accepted 31 August 2015

Available online ■ ■ ■

KEYWORDS

multidrug-resistance;
O-serogroup;
UPEC;
virulence factors

Abstract *Background/Purpose:* Uropathogenic *Escherichia coli* (UPEC) strains isolated from patients with community-acquired urinary tract infections (UTIs) were assessed to determine the prevalence of virulence genes, antibiotic resistance, and the O-serogroup of the strains. *Methods:* Consenting patients with community-acquired UTI were enrolled at Unidad Médica Familiar Number 64 (Instituto Mexicano del Seguro Social, Estado de Mexico, Mexico) and 321 urine samples were collected. Polymerase chain reaction (PCR) was used to assess 24 virulence genes and 14 O-serogroups. The Kirby-Bauer method was used to evaluate the antibiotic susceptibility of the isolated strains to 12 commonly used antibiotics. *Results:* A total of 194 strains were identified as *E. coli* using standard biochemical tests, followed by PCR amplification of 16S ribosomal RNA gene. Only 58.2% of the strains belonged to the assessed 14 O-serogroups. The serogroups O25, O15, O8, and O75 were present in 20.6%, 17%, 6.1%, and 4.6% of strains, respectively. The most frequently occurring virulence genes among UPEC strains included *kpsMT* (92.2% strains), *usp* (87.1%), *irp2* (79.3%), *iha* (64.9%), *fim* (61.3%), *set* (36%), *astA* (33.5%), *pap* (24.7%), and *papGII* (21.1%). In addition, 97% of the strains were multi-drug resistant (coresistance to 3–11 antibiotics).

* Corresponding author. FES Iztacala, Universidad Nacional Autónoma de México. Avenida de Los Barrios 1, Los Reyes Iztacala, Tlalnepantla, 54090, Estado de México, México
E-mail address: vacasergio@gmail.com (S. Vaca).

<http://dx.doi.org/10.1016/j.jmii.2015.08.005>

1684-1182/Copyright © 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.

Please cite this article in press as: Paniagua-Contreras GL, et al., Virulence factors, antibiotic resistance phenotypes and O-serogroups of *Escherichia coli* strains isolated from community-acquired urinary tract infection patients in Mexico, Journal of Microbiology, Immunology and Infection (2015), <http://dx.doi.org/10.1016/j.jmii.2015.08.005>

Conclusion: The isolated UPEC strains predominantly belonged to three serogroups (O25, O15, and O8), harboured numerous virulence genes, and are multiresistant to antibiotics. The findings of this study could be used to orient UTI treatment strategies and in epidemiological studies in Mexico.

Copyright © 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.

Introduction

Urinary tract infection (UTI) is one of the most commonly occurring bacterial infections¹ and 70–95% of the UTIs are caused by uropathogenic *Escherichia coli* (UPEC).² Virulence factors related to UPEC include genes encoding adhesins (*pap*, *papG* allele I, *papG* allele II, *papG* allele III, *sfa*, *afal*, *fim*, *iha*, and *tsh*); genes related to the iron acquisition systems (*iuc*, *iroN*, and *irp2*); protectin genes (*kpsMT* and *iss*); and genes encoding toxins (*set*, *astA* *cnf1*, *hlyA*, *vat*, *usp*, and *cva/cvi*).^{3,4}

UPEC strains are routinely serotyped using the common O antisera and the serogroups O1, O2, O4, O6, O7, O8, O15, O16, O18, O21, O22, O25, O75, and O83 are preferentially associated with UPEC strains.^{3,5} Serogroup assays are used for accurate *E. coli* identification and for epidemiological investigations of *E. coli* outbreaks.

The treatment of UTIs caused by UPEC often requires antimicrobial therapy. However, currently there has been a rise in the occurrence of antibiotic-resistant UPEC strains, and UTIs are considered a serious health concern.¹

Given the clinical importance of UTIs, the aim of this work was to determine the prevalence of virulence genes, resistance to antibiotics, and the O-serogroup of UPEC strains isolated from patients with community-acquired UTIs in Mexico.

Methods

Sample collection and *E. coli* strains

Three hundred and twenty-one urine samples were collected from patients with community-acquired UTIs (247 women and 74 men; age range, 20–70 years) from Unidad Médica Familiar (UMF) Number 64 (Instituto Mexicano del Seguro Social), located in Estado de Mexico, Mexico, from August 2013 to December 2013. Patient inclusion criteria were as follows: persons with signs and symptoms of UTI and accepting to participate in the study by signing the informed consent letter were enrolled. Patients undergoing antibiotic treatment were excluded. The local ethics committee of UMF approved the study. The samples were cultured on blood agar and MacConkey agar (Bioxon, Mexico, Mexico) at 37°C overnight. The identification of *E. coli* was performed by IMViC tests, and confirmed by 16S ribosomal RNA (rRNA) gene polymerase chain reaction (PCR) amplification as described elsewhere.^{6,7} For each test, *E. coli* ATCC 11775 was used as the control strain. An UTI caused by *E. coli* was recognized if it was accompanied by symptoms suggestive of infection and a culture of a

clean-catch urine sample with at least 10⁵ colony forming units of *E. coli* per milliliter.

DNA extraction

DNA extraction was performed using the boiling method. Bacteria were grown in brain-heart infusion broth (BHI; Bioxon) at 37°C overnight. The bacterial overnight growth culture (1.5 mL) was pelleted, the culture supernatant was discarded, and the cell pellet was suspended in 200 µL of sterile water. The resuspended pellet was then incubated at 100°C for 10 minutes and centrifuged at 10,000g for 5 minutes. The pellet was discarded and the DNA, present in the supernatant, was stored at –20°C until required for assays.

Antibiotic susceptibility testing

The standard disc diffusion method of Kirby-Bauer by using Mueller Hinton agar (Bioxon) was performed to evaluate antibiotic susceptibility. The antibiotic susceptibility of gram-negative bacteria was assessed by using 12 different antibiotic-loaded discs (Bio-Rad, Mexico). Results were interpreted in accordance with the Clinical and Laboratory Standards Institute guidelines.⁸ The following antibiotics were used at the indicated concentrations: ampicillin (10 µg), cefalotin (30 µg), cefotaxime (30 µg), carbenicillin (100 µg), ceftriaxone (30 µg), chloramphenicol (30 µg), pefloxacin (5 µg), gentamicin (10 µg), nitrofurantoin (300 µg), netilmicin (30 µg), amikacin (30 µg), and trimethoprim-sulfamethoxazole (25 µg). For each test, *E. coli* ATCC 11775 was used as the control strain. In accordance with the manufacturer of the discs (Bio-Rad), strains were considered resistant to carbenicillin if the diameter of inhibition halo was ≤ 19 mm; and resistant to pefloxacin if the diameter of inhibition halo was ≤ 14 mm.

Detection of virulence genes and serogroups of UPEC strains

The primer sequences and PCR cycling conditions described by Momtaz et al⁹ were used to assess the prevalence of the following virulence genes: (1) adhesins: *pap* (pilus associated with pyelonephritis), *papG* allele I, *papG* allele II, *papG* allele III, *sfa* (S fimbriae), *afal* (afimbrial adhesin I), *fim* (type-1 fimbriae), *iha* (nonhemagglutinating adhesin), and *tsh* (temperature-sensitive hemagglutinin); (2) nutrition: *iuc* (aerobactin), *iroN* (iron), and *irp2* (iron-repressible protein); (3) protectins: *kpsMT* (K-antigen) and *iss* (increased serum survival protein); and (4) toxins: *set*

Table 1 Virulence genes and serogroups of UPEC strains

UPEC serogrup (n = 194)	Adhesins No. of strains (%)										Nutrition			Protectins		Toxins						<i>she</i> PAI			
	No. (%)	<i>pap</i>	<i>papGI</i>	<i>papGII</i>	<i>papGIII</i>	<i>sfa</i>	<i>afa</i>	<i>fim</i>	<i>lha</i>	<i>tsh</i>	<i>iuc</i>	<i>iroN</i>	<i>irp2</i>	<i>kpsMT</i>	<i>iss</i>	<i>astA</i>	<i>cnf1</i>	<i>hlyA</i>	<i>vat</i>	<i>usp</i>	<i>cva/cvi</i>	<i>set</i>	<i>sigA</i>	<i>sap</i>	<i>pic</i>
		48	23	41	12	24	25	119	126	10	32	23	154	179	7	65	14	30	11	169	9	70	8	3	5
		(24.7)	(11.8)	(21.1)	(6.2)	(12.3)	(12.8)	(61.3)	(64.9)	(5.1)	(16.5)	(11.8)	(79.3)	(92.2)	(5.9)	(33.5)	(7.2)	(15.4)	(5.6)	(87.1)	(4.6)	(36)	(4.1)	(1.5)	(2.5)
01	5 (2.5)	1	—	3	1	1	1	4	3	—	1	2	4	4	—	3	1	1	—	4	—	3	—	—	—
02	1 (0.5)	—	—	1	—	—	—	1	1	—	—	—	1	1	—	—	—	—	—	1	—	1	—	—	—
04	0 (0)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
06	2 (1.0)	—	1	—	1	1	—	—	2	—	—	2	—	2	—	1	—	—	—	2	—	—	—	—	2
07	1 (0.5)	—	—	—	—	—	—	1	—	—	—	—	1	1	—	—	—	—	—	1	—	—	—	—	—
08	12 (6.1)	1	3	2	—	4	1	7	5	5	4	3	9	11	1	6	1	3	1	9	2	2	—	1	—
015	33 (17)	12	5	9	5	6	6	22	25	—	5	1	31	31	1	8	4	7	3	29	—	16	1	—	—
016	7 (3.6)	1	2	1	—	1	—	5	5	—	—	1	7	7	—	2	—	1	—	7	—	2	—	—	—
018	0 (0)	—	—	—	—	—	—	—	5	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
021	2 (1.0)	—	—	—	—	1	1	2	1	—	—	—	1	1	—	2	—	—	—	2	—	—	—	—	—
022	1 (0.5)	—	—	—	—	—	—	—	—	—	—	—	1	1	—	1	—	—	—	1	—	—	—	—	—
025	40 (20.6)	18	4	19	1	8	7	30	39	3	11	2	36	40	1	13	5	14	1	34	1	21	4	1	—
075	9 (4.6)	2	4	—	1	—	—	5	8	2	2	1	9	9	—	5	—	—	2	5	2	6	—	1	—
083	0 (0)	—	—	—	—	—	—	—	—	—	—	—	—	0	—	—	—	—	—	—	—	—	—	—	—
Not detected	81 (41.7)	13	4	6	3	12	—	42	32	0	9	11	54	71	4	24	3	4	—	74	4	19	3	0	3

UPEC = uropathogenic *Escherichia coli*.

(*Shigella* enterotoxin 1), *astA* (enteroaggregative heat stable toxin), *cnf1* (cytotoxic necrotizing factor 1), *hlyA* (hemolysin), *vat* (vacuolating autotransporter toxin), *usp* (uropathogenic specific protein), and *cva/cvi* (colicin V plasmid operon genes). To determine the presence of *set* gene in the *she* pathogenicity island (*she* PAI), the *sigA*, *pic*, and *sap* genes, which are also present in pathogenicity-associated islands (PAIs), were detected using PCR as described elsewhere.¹⁰

The primers and PCR conditions used for detection of UPEC O1, O2, O4, O6, O7, O8, O15, O16, O18, O21, O22, O25, O75, and O83 serogroups were described by Li et al.¹¹

Statistical analysis

The frequencies of the virulence-related genes among the serogroups of UPEC strains were analyzed using Chi-square tests. A *p* value < 0.05 was considered significant.

Results

Detection of serogroups and virulence genes of UPEC strains

A total of 194 strains isolated from patients with community-acquired UTIs were identified as *E. coli* by using standard biochemical tests and the identity was confirmed using PCR amplification of the 16S rRNA gene. Only 58.2% (*n* = 113) of the strains belonged to 11 of the 14 assessed serogroups (Table 1). The serogroups O25, O15, O8, and O75 were prevalent in 20.6% (40), 17% (33), 6.1% (12), and 4.6% (9) isolated UPEC strains, respectively (Table 1).

The adhesion genes with the highest prevalence were *iha* (64.9%, *n* = 126), *fim* (61.3%, *n* = 119), and *pap* (24.7%, *n* = 48). The iron acquisition genes *irp2* and *iuc* were present in 79.3% (154) and 16.5% (32) of the isolated UPEC strains, respectively. The most commonly present gene for host defense avoidance was the capsular polysaccharide production related gene, *kpsMT* (92.2%, *n* = 179). The toxin-coding genes *usp*, *set*, *astA*, and *hlyA* were present in 87.1% (169), 36% (70), 33.5% (65), and 15.4% (30) strains, respectively. The *she* PAI-associated *sigA*, *sap*, and *pic* genes were found in a very low number of the strains (Table 1).

UPEC strains belonging to serogroups O25 (20.6%, *n* = 40), O15 (17%, *n* = 33), and O8 (6.1%, *n* = 12) harbored the highest number of associated virulence factors (Table 1).

The virulence gene frequencies among the serogroups of UPEC strains were different (*p* < 0.05).

Multidrug resistance

Almost 98% of the UPEC strains were resistant to cefalotin (97.9%, *n* = 190), ampicillin (97.4%, *n* = 189), or carbenicillin (97.4%, *n* = 189). Seventy-six percent of strains (*n* = 148) were resistant to pefloxacin and 72.7% (*n* = 141) strains were resistant to cefotaxime (Table 2). Overall, a total of 188 strains (96.9%) were resistant to three to 11 antibiotics (Table 3).

Table 2 Antibiotic resistance of the UPEC strains

Antibiotic	Number (%)
Cefalotin (Cf)	190 (97.9)
Ampicillin (Am)	189 (97.4)
Carbenicillin (Cb)	189 (97.4)
Pefloxacin (Pef)	148 (76.3)
Cefotaxime (Ctx)	141 (72.7)
Trimethoprim & sulfamethoxazole (Sxt)	128 (66.0)
Ceftriaxone (Cro)	95 (48.9)
Gentamycin (Ge)	97 (50.0)
Nitrofurantoin (Nf)	87 (44.8)
Netilmicin (Net)	72 (37.1)
Chloramphenicol (Cl)	50 (25.8)
Amikacin (Ak)	28 (14.4)

Patterns of virulence genotypes, antibiotic resistance phenotypes, and serogroup of the UPEC strains

A total of 138 distinct arrangements of antibiotic resistance phenotypes and virulence markers were identified in the UPEC strains. None of the patterns was predominantly prevalent (Table 3). The most abundant pattern (No. 1; *fim/iha/irp2/kpsMT/usp/set/cefalotin/ampicillin/carbenicillin*) was represented only by 11 strains (5.6%) that belonged to serogroups O25 (6 strains), O15 (1 strain), O75 (1 strain), and to O-serogroup not assessed in this study (3 strains).

Discussion

Recently, several different prevalence rates of UPEC strains related to UTIs have been described in different countries.^{12–14} Furthermore, the antibiotic resistance of UPEC strains is of increasing public health concern.¹⁵ In this study, we identified *E. coli* in 60.4% (*n* = 194) of the 321 urine samples obtained from patients with community-acquired UTIs. Unlike diarrheagenic *E. coli* strains that have been classified into six different pathotypes,¹⁶ UPEC strains are genetically more diverse and may share virulence determinants with diarrheagenic *E. coli*.³ Four serogroups (O25, O15, O8, and O75) were predominantly prevalent among the UPEC strains assessed in this study. It has been previously reported that O25 was the most frequent serotype found in uropathogenic *E. coli* in Mexico City.¹⁷

Genes encoding fimbrial adhesive systems are the most commonly occurring virulence factors in *E. coli* that cause UTIs.¹⁸ The adhesion factors promote colonization, invasion, and replication within uroepithelial cells¹⁹ and precede the expression of other bacterial products such as toxins, iron acquisition systems, and host defense avoidance mechanisms (protectins), which are encoded on PAIs.²⁰ The most prevalent adhesion genes found in our study were *iha* (64.9%, *n* = 126), *fim* (61.3%, *n* = 119), *pap* (24.7%, *n* = 48), and *papGII* (21.1%, *n* = 41; Table 1). The adhesion genes were mainly associated with serogroups O25, O15, and O8 (Table 1). These findings are in agreement

Table 3 Patterns of virulence genes, antibiotic resistance phenotypes, and O-serogroup of the UPEC strains

Number of pattern	Patterns of virulence genes and antibiotic resistance phenotypes	Serogroups														Number of strains	%	
		01	02	04	06	07	08	015	016	018	021	022	025	075	083			Not detected
1	<i>fim/iha/irp2/kpsMT/usp/set/Cf/Am/Cb</i>	—	—	—	—	—	—	1	—	—	—	—	6	1	—	3	11	5.6
2	<i>fim/iha/irp2/kpsMT/usp/astA/Cf/Am/Cb</i>	—	—	—	—	—	—	1	—	—	1	—	2	1	—	4	9	4.6
3	<i>fim/iha/iuc/irp2/kpsMT/usp/set/Cf/Am/Ctx/Pef/Cb</i>	—	—	—	—	—	—	1	—	—	—	—	2	—	—	4	7	3.6
4	<i>fim/iha/irp2/kpsMT/usp/astA/set/Cf/Am/Cb</i>	—	—	—	—	—	—	1	—	—	—	—	4	1	—	0	6	3.1
5	<i>fim/irp2/set/Cf/Am/Cb</i>	—	—	—	—	—	—	—	—	—	—	—	1	—	—	4	5	2.5
6	<i>fim/irp2/astA/set/Cf/Am/Cb</i>	—	—	—	—	—	—	1	—	—	—	—	—	—	—	3	4	2.0
7	<i>fim/papGII/iha/irp2/kpsMT/usp/set/Cf/Am/Ctx/Cb</i>	—	—	—	—	—	—	1	1	—	—	—	—	2	—	0	4	2.0
8	<i>fim/iha/irp2/kpsMT/usp/Cf/Am/Cb</i>	—	—	—	—	—	—	3	—	—	—	—	1	—	—	0	4	2.0
9	<i>pap/iha/irp2/kpsMT/usp/set/Cf/Cro/Am/Sxt/Ctx/Net/Pef/Ge/Cb</i>	—	—	—	—	—	—	2	1	—	—	—	—	—	—	0	3	1.5
10	<i>fim/irp2/kpsMT/astA/Cf/Am/Cb</i>	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3	3	1.5
11	<i>pap/papGII/sfa/fim/iha/irp2/kpsMT/cnf1/hlyA/usp/Cf/Am/Net/Pef/Ge/Cb</i>	—	—	—	—	—	—	2	—	—	—	—	—	—	—	0	2	1.0
12	<i>sfa/hlyA/set/Cf/Cro/Am/Sxt/Ctx/Pef/Nf/Ge/Cb</i>	—	—	—	—	—	—	—	—	—	—	—	1	—	—	1	2	1.0
13	<i>hlyA/fim/set/irp2/Cf/Am/Ctx/Pef/Cb</i>	—	—	—	—	—	—	—	1	—	—	—	—	—	—	1	2	1.0
14	<i>afa/fim/astA/Cf/Am/Ctx/Pef/Nf/Cb</i>	—	—	—	—	—	1	—	—	—	—	—	—	—	—	1	2	1.0
15	<i>papGII/sfa/fim/iha/irp2/kpsMT/hlyA/usp/Am/Pef/Cb</i>	—	—	—	—	—	—	1	—	—	—	—	1	—	—	0	2	1.0
16	<i>fim/iha/iroN/irp2/kpsMT/cva-cv1/Cf/Am</i>	—	—	—	—	—	—	1	—	—	—	—	—	1	—	0	2	1.0
17	<i>pap/papGII/iha/irp2/kpsMT/usp/Cf/Am/Cb</i>	—	—	—	—	1	—	—	—	—	—	—	1	—	—	0	2	1.0
18–138	Other combinations	5	1	0	2	0	9	20	4	0	1	1	21	3	0	57	124	64.0

Ak = amikacin; Am = ampicillin, Cb = carbenicillin, Cf = cefalotin, Cl = chloramphenicol; Cro = ceftriaxone, Ctx = cefotaxime, Ge = gentamycin, Net = netilmicin; Nf = nitrofurantoin, Pef = pefloxacin, Sxt = trimethoprim and sulfamethoxazole; UPEC = uropathogenic *Escherichia coli*.

with those previously reported for UPEC strains ($n = 162$) isolated from cystitis²¹ and for UPEC strains ($n = 202$) isolated from patients with community-acquired UTIs.²² The *fim*, *pap*, *sfa*, and *afa* genes have been associated with cystitis and pyelonephritis.²³ Previous studies have shown that *papGII* is associated with pyelonephritis and bacteraemia and that class *papGIII* is associated with cystitis; although strains associated with pyelonephritis and bacteraemia have also been shown to harbor *papGIII* genes.^{24,25} In this study, *iha* was the most frequent adhesion gene detected in the UPEC strains (Table 1). It has been described that *iha* confers nonadherent *E. coli* K12 adherence capability to HeLa cells, and the encoded protein (Iha) was first identified from an *E. coli* O157:H7 isolate.²⁶

In this study the iron acquisition system genes, *irp2* (79.3%, $n = 154$) and *iuc* (16.5%, $n = 32$; Table 1), were the most prevalent in the serogroups O25, O15, and O8. The prevalence rates obtained in our study were higher than those previously described for UPECs,²⁷ but lower than those described for avian pathogenic *E. coli*, indicating that frequencies of iron acquisition system genes vary according to location and host.²⁸ Iron is an essential element for the survival of *E. coli* and facilitates numerous cellular activities such as peroxide reduction, electron transport, and nucleotide biosynthesis.²⁹

High prevalence of virulence markers in the UPEC strains isolated from patients with community-acquired UTIs suggests that these strains are highly pathogenic. The capsule-encoding gene, *kpsMT*, is commonly prevalent in UPEC strains associated with pyelonephritis than in strains associated with other UTIs.³⁰ In this study, > 92% (179) of the isolated strains were positive for *kpsMT* (Table 1). Furthermore, the percentage of strains with toxin-coding genes *usp*, *set*, *astA*, and *hlyA* were 87.1%, 36%, 33.5%, and 15.4%, respectively. These data indicated that the isolated strains have the potential to produce toxins. Different gene prevalence frequencies have been described for UPECs isolated in other countries.^{21,22,31} Other virulence genes that were detected in UPECs were as follows: *usp*, which has been shown to occur more frequently in strains associated with pyelonephritis than with cystitis³²; *set* encoding the ShET-1 (*Shigella* enterotoxin 1) toxin that has been shown to induce fluid accumulation in the rabbit ileal loop and may account for initial watery diarrhea that can occur in early stages of *Shigella flexneri* 2a infections³³; *astA* encoding the EAST-1 (enteroaggregative heat-stable toxin 1) toxin that plays a role in enteroaggregative *E. coli* (EAEC) pathogenicity³⁴ and *hlyA* in UPEC increased urothelial damage *in vivo*.³⁵

The emergence of *E. coli* isolates that have multiple-antibiotic-resistant phenotypes, which confers resistance to four or more unrelated families of antibiotics has been previously reported and is considered a serious health concern.^{36,37} Most UPEC strains that were characterized in this study were resistant to cefalotin, ampicillin, carbenicillin, pefloxacin, and cefotaxime (Table 2), with 96.9% ($n = 188$) of strains showing multi-drug resistance (core-sistance to 3–11 antibiotics). This finding is in agreement with previous findings on antibiotic resistance of UPEC strains isolated from patients from other countries.²² The high prevalence of multiple-antibiotic resistance in UPECs may be related with the frequent use of these drugs to

treat UTIs in Mexico. Of particular concern is the finding that a high percentage of *E. coli* strains are resistant to trimethoprim/sulfamethoxazole (66%) and nitrofurantoin (44.8%) because these antibiotics, and ciprofloxacin, are the therapeutic agents used in the Mexican social security health system, Instituto Mexicano del Seguro Social, to treat UTIs.

The transfer of resistance determinants by mobile genetic elements, including plasmids, transposons, and gene cassettes present in integrons³⁸ and the alteration in *mar* locus regulation may be important factors that can contribute to the increase in the prevalence of multidrug-resistant bacteria.

In this study, different patterns of combinations of the virulence markers and antibiotic resistant phenotypes were identified in the UPEC strains (Table 3). All the strains from patterns 1–4, 7–11, and 15–17 (36%, $n = 70$) had genes for adhesins, nutrition, protectins, toxins, and resistance to cefalotin, ampicillin, and carbenicillin (resistance to 1 of the aforementioned antibiotics was absent in strains with patterns 15 and 16), and mainly belonged to serogroups O15, O25, and O8. The pattern 1 (*fim/iha/irp2/kpsMT/usp/set/cefalotin/ampicillin/carbenicillin*) was the most frequently present (Table 3). The association between *fimA* and *kpsMT* genes that was identified in our study was previously characterized using *E. coli* isolated from UTIs and asymptomatic bacteriuria in children.³¹ In this study we found that genes *fim* and *kpsMT* were present in a high percentage of the *E. coli* strains (57.7%, $n = 110$, data not shown). The simultaneous possession of these genes may enhance the pathogenesis of *E. coli* due to the increased adhesion (fimbriae encoded by *fim*) and the evasion of phagocytosis (capsule encoded by *kpsMT*).

In conclusion, to our knowledge, in addition to the work of Molina-López et al.,¹⁷ this is the second comprehensive study that characterizes the genotype of uropathogenic *E. coli* in Mexico. The strains characterized here showed the coexistence of different combinations of virulence markers and confirmed the prevalence of antibiotic-resistant phenotypes among the distinct serogroups. The findings of our study have potential application in designing UTI treatment strategies against UTIs caused by *E. coli* and for epidemiological studies in Mexico.

Conflicts of interest

All contributing authors declare no conflicts of interest.

Acknowledgments

Research was carried out thanks to the Program UNAM-DGAPA-PAPIIT IN218614, and FESI-DIP-PAPCA-2014-23. We would like to thank Editage (www.editage.com) for English language editing.

References

1. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infect Dis Clin North Am* 2014;28:1–13.

2. George DB, Manges AR. A systematic review of outbreak and non-outbreak studies of extraintestinal pathogenic *Escherichia coli* causing community-acquired infections. *Epidemiol Infect* 2010;138:1679–90.
3. Abe CM, Salvador FA, Falsetti IN, Vieira MA, Blanco J, Blanco JE, et al. Uropathogenic *Escherichia coli* (UPEC) strains may carry virulence properties of diarrhoeagenic *E. coli*. *FEMS Immunol Med Microbiol* 2008;52:397–406.
4. Chiou YY, Chen MJ, Chiu NT, Lin CY, Tseng CC. Bacterial virulence factors are associated with occurrence of acute pyelonephritis but not renal scarring. *J Urol* 2010;184:2098–102.
5. Orskov I, Orskov F, Birch-Andersen A, Kanamori M, Svanvorg-Edén C. O, K, H, and fimbrial antigens in *Escherichia coli* serotypes associated with pyelonephritis and cystitis. *Scand J Infect Dis Suppl* 1982;33:18–25.
6. Lane DJ, Pace B, Olsen GJ, Stahl DA, Sogin ML, Pace NR. Rapid determination of 16S ribosomal RNA sequences for phylogenetic analyses. *Proc Natl Acad Sci U S A* 1985;82:6955–9.
7. Warsen AE, Krug MJ, LaFrentz S, Stanek DR, Loge FJ, Call DR. Simultaneous discrimination between 15 fish pathogens by using 16S ribosomal DNA PCR and DNA microarrays. *Appl Environ Microb* 2004;70:4216–21.
8. Wayne PA. Performance standards for antimicrobial susceptibility testing. In: *CLSI, Twenty-Third Informational Supplement M100-S23*. Wayne, Pennsylvania, USA: Clinical and Laboratory Standards Institute; 2013. p. 74.
9. Momtaz H, Karimian A, Madan M, Dehkordi SF, Ranjbar R, Sarshar M, et al. Uropathogenic *Escherichia coli* in Iran: Serogroup distributions, virulence factors and antimicrobial resistance properties. *Ann Clin Microbiol Antimicrob* 2013;12:8.
10. Soto SM, Guiral E, Bosch J, Vila J. Prevalence of the *set-1B* and *astA* genes encoding enterotoxins in uropathogenic *Escherichia coli* clinical isolates. *Microb Pathog* 2009;47:305–7.
11. Li D, Liu B, Chen M, Guo D, Guo X, Liu F, et al. A multiplex PCR method to detect 14 *Escherichia coli* serogroups associated with urinary tract infections. *J Microbiol Methods* 2010;82:71–7.
12. Derakhshandeh A, Firouzi R, Motamedifar M, Motamedi Borojeni A, Bahadori M, Arabshahi S, et al. Distribution of virulence genes and multiple drug-resistant patterns amongst different phylogenetic groups of uropathogenic *Escherichia coli* isolated from patients with urinary tract infection. *Lett Appl Microbiol* 2015;60:148–54.
13. Mohajeri P, Khademi H, Ebrahimi R, Farahani A, Rezaei M. Frequency distribution of virulence factors in uropathogenic *Escherichia coli* isolated from Kermanshah in 2011–2012. *Int J Appl Basic Med Res* 2014;4:111–6.
14. Lee DS, Choe HS, Lee SJ, Bae WJ, Cho HJ, Yoon BI, et al. Antimicrobial Susceptibility Pattern and Epidemiology of Female Urinary Tract Infections in South Korea, 2010–2011. *Antimicrob Agents Chemother* 2013;57:5384–93.
15. Zhanel G, Hisanaga T, Laing N, DeCorby MR, Nichol KA, Weshnowski B, et al. Antibiotic resistance in *Escherichia coli* outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). *Int J Antimicrob Agents* 2006;27:468–75.
16. Kaper JB, Nataro JP, Mobley HL. Pathogenic *Escherichia coli*. *Nature Rev* 2004;2:123–40.
17. Molina-López J, Aparicio-Ozores G, Ribas-Aparicio RM, Gaviñanes-Parra S, Chávez-Barrocal ME, Hernández-Castro R, et al. Drug resistance, serotypes, and phylogenetic groups among uropathogenic *Escherichia coli* including O25-ST131 in Mexico City. *J Infect Dev Ctries* 2011;5:840–9.
18. Connell H, Hedlund M, Agace W, Svanborg C. Bacterial attachment to uro-epithelial cells: mechanisms and consequences. *Adv Dent Res* 1997;11:50–8.
19. Mulvey MA. Adhesion and entry of uropathogenic *Escherichia coli*. *Cell Microbiol* 2002;4:257–71.
20. Blum G, Ott M, Lischewski A, Ritter A, Imrich H, Tschape H, et al. Excision of large DNA regions termed pathogenicity islands from tRNA-specific loci in the chromosome of an *Escherichia coli* wild-type pathogen. *Infect Immun* 1994;62:606–14.
21. Tiba MR, Yano T, Leite Dda S. Genotypic characterization of virulence factors in *Escherichia coli* strains from patients with cystitis. *Rev Inst Med Trop Sao Paulo* 2008;50:255–60.
22. Zhao L, Chen X, Zhu X, Yang W, Dong L, Xu X, et al. Prevalence of virulence factors and antimicrobial resistance of uropathogenic *Escherichia coli* in Jiangsu province (China). *Urology* 2009;74:702–7.
23. Tarchouna M, Ferjani A, Ben-Selma W, Boukadida J. Distribution of uropathogenic virulence genes in *Escherichia coli* isolated from patients with urinary tract infection. *Int J Infect Dis* 2013;17:e450–3.
24. Féria C, Machado J, Duarte Correia J, Gonçalves J, Gaastra W. Distribution of *papG* alleles among uropathogenic *Escherichia coli* isolated from different species. *FEMS Microbiol Lett* 2001;202:205–8.
25. Johnson JR, Russo TA, Brown JJ, Stapleton A. *papG* alleles of *Escherichia coli* strains causing first-episode or recurrent acute cystitis in adult women. *J Infect Dis* 1998;177:97–101.
26. Tarr PI, Bilge SS, Vary JC, Jelacic Jr S, Habeeb RL, Ward TR, et al. *Iha*: a novel *Escherichia coli* O157:H7 adherence-conferring molecule encoded on a chromosomal region of conserved structure. *Infect Immun* 2000;68:1400–7.
27. Karimian A, Momtaz H, Madani M. Detection of uropathogenic *Escherichia coli* virulence factors in patients with urinary tract infections in Iran. *Afr J Microbiol Res* 2012;6:6811–6.
28. Jeong YW, Kim TE, Kim JH, Kwon HJ. Pathotyping avian pathogenic *Escherichia coli* strains in Korea. *J Vet Sci* 2012;13:145–52.
29. Braun V. Iron uptake mechanisms and their regulation in pathogenic bacteria. *Intl J Med Microbiol* 2001;291:67–79.
30. Jann K, Jann B. Capsules of *Escherichia coli*. In: Sussman M, editor. *Escherichia coli mechanisms of virulence*. Cambridge: Cambridge University Press; 1997. p. 113–4.
31. Yun KW, Kim HY, Park HK, Kim W, Lim IS. Virulence factors of uropathogenic *Escherichia coli* of urinary tract infections and asymptomatic bacteriuria in children. *J Microbiol Immunol Infect* 2014;47:455–61.
32. S1 Kanamaru, Kurazono H, Ishitoya S, Terai A, Habuchi T, Nakano M, et al. Distribution and genetic association of putative uropathogenic virulence factors *iroN*, *iha*, *kpsMT*, *ompT* and *usp* in *Escherichia coli* isolated from urinary tract infections in Japan. *J Urol* 2003;170:2490–3.
33. A1 Fasano, Noriega FR, Maneval Jr DR, Chanasongcram S, Russell R, Guandalini S, et al. *Shigella* enterotoxin 1: an enterotoxin of *Shigella flexneri* 2a active in rabbit small intestine *in vivo* and *in vitro*. *J Clin Invest* 1995;95:2853–61.
34. Savarino SJ, McVeigh A, Watson J, Cravioto A, Molina J, Echeverria P, et al. Enterotoxigenic *Escherichia coli* heat-stable enterotoxin is not restricted to enterotoxigenic *E. coli*. *J Infect Dis* 1996;173:1019–22.
35. Smith YC, Rasmussen SB, Grande KK, Conran RM, O'Brien AD. Hemolysin of uropathogenic *Escherichia coli* evokes extensive shedding of the uroepithelium and hemorrhage in bladder tissue within the first 24 hours after intraurethral inoculation of mice. *Infect Immun* 2008;76:2978–90.
36. Ariza RR, Cohen SP, Bachhawat N, Levy SB, Demple B. Repressor mutations in the *marRAB* operon that activate oxidative stress genes and multiple antibiotic resistance in *Escherichia coli*. *J Bacteriol* 1994;176:143–8.

37. Kazemnia A, Ahmadi M, Dilmaghani M. Antibiotic resistance pattern of different *Escherichia coli* phylogenetic groups isolated from human urinary tract infection and avian colibacillosis. *Iran Biomed J* 2014;**18**:219–24.
38. Hall RM, Collis CM. Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons. *Drug Resist Updat* 1998;**1**:109–19.